Research programme: angiogenesis inhibitors - Bausch & Lomb/Teva Pharmaceutical Industries

Drug Profile

Research programme: angiogenesis inhibitors - Bausch & Lomb/Teva Pharmaceutical Industries

Alternative Names: Eye disorder therapeutics - Bausch & Lomb/Teva Pharmaceutical Industries

Latest Information Update: 30 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 13 Dec 2005 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
  • 13 Dec 2005 Preclinical trials in Diabetic macular oedema in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top